<DOC>
	<DOCNO>NCT02652429</DOCNO>
	<brief_summary>An Open-Label Long-Term Safety Study Inhaled Nitric Oxide ( iNO ) Pulmonary Arterial Hypertension ( PAH )</brief_summary>
	<brief_title>Long-Term Extension Study Inhaled Nitric Oxide ( iNO ) PAH</brief_title>
	<detailed_description>An open-label , long-term study evaluate safety inhale nitric oxide ( iNO ) subject pulmonary arterial hypertension ( PAH ) participate IK-7001-PAH-201 provide patient continue access chronic iNO time approval trial discontinue due lack efficacy .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Signed Informed Consent Form prior initiation study mandate procedure assessment . PAH subject complete EOS assessment IK7001PAH201 study continue drug/device usage EOS . Subjects willing consider judgement Investigator able use INOpulse device 24 hour per day could benefit continued use . All female subject must willing continue take adequate precaution avoid pregnancy use suitable method birth control . Subjects require treatment riociguat Subjects early discontinue drug/device usage due withdrawal consent AE require termination treatment IK7001PAH201</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Inhaled Nitric Oxide</keyword>
	<keyword>iNO</keyword>
</DOC>